Effectiveness and Safety of Rituximab in Recalcitrant Pemphigoid Diseases

Aniek Lamberts*, H. Ilona Euverman, Jorrit B. Terra, Marcel F. Jonkman, Barbara Horvath

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

78 Citations (Scopus)
432 Downloads (Pure)

Abstract

Introduction: Rituximab (RTX) is a monoclonal antibody targeting CD20, a transmembrane protein expressed on B cells, causing B cell depletion. RTX has shown great efficacy in studies of pemphigus vulgaris, but data of pemphigoid diseases are limited.

Objective: To assess the effectiveness and safety of RTX in pemphigoid diseases.

Methods: The medical records of 28 patients with pemphigoid diseases that were treated with RTX were reviewed retrospectively. Early and late endpoints, defined according to international consensus, were disease control (DC), partial remission (PR), complete remission (CR), and relapses. Safety was measured by reported adverse events.

Results: Patients with bullous pemphigoid (n = 8), mucous membrane pemphigoid (n = 14), epidermolysis bullosa acquisita (n = 5), and linear IgA disease (n = 1) were included. Treatment with 500 mg RTX (n = 6) or 1,000 mg RTX (n = 22) was administered on days 1 and 15. Eight patients received additional 500 mg RTX at months 6 and 12. Overall, DC was achieved in 67.9%, PR in 57.1%, and CR in 21.4% of the cases. During follow-up, 66.7% patients relapsed. Repeated treatment with RTX led to remission (PR or CR) in 85.7% of the retreated cases. No significant difference in response between pemphigoid subtypes was found. IgA-dominant cases (n = 5) achieved less DC (20 vs. 81.3%; p = 0.007), less PR (20 vs. 62.5%; p = 0.149), and less CR (0 vs. 18.8%; p = 0.549) compared to IgG-dominant cases (n = 16). Five severe adverse events and three deaths were reported. One death was possibly related to RTX and one death was disease related.

Conclusion: RTX can be effective in recalcitrant IgG-dominant pemphigoid diseases, however not in those where IgA is dominant.

Original languageEnglish
Article number248
Number of pages9
JournalFrontiers in Immunology
Volume9
DOIs
Publication statusPublished - 19-Feb-2018

Keywords

  • pemphigoid diseases
  • autoimmune bullous diseases
  • rituximab
  • IgA
  • mucous membrane pemphigoid
  • linear IgA disease
  • epidermolysis bullosa acquisita
  • case series
  • IGA BULLOUS DERMATOSIS
  • CONSENSUS STATEMENT
  • CONVENTIONAL THERAPY
  • RHEUMATOID-ARTHRITIS
  • COMBINATION THERAPY
  • MONOCLONAL-ANTIBODY
  • PROGNOSTIC-FACTORS
  • CASE SERIES
  • FOLLOW-UP
  • B-CELLS

Fingerprint

Dive into the research topics of 'Effectiveness and Safety of Rituximab in Recalcitrant Pemphigoid Diseases'. Together they form a unique fingerprint.

Cite this